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Objectives: We hypothesize that persistent alterations in molecular signaling may drive recurrent pathologic
remodeling even after the reduction of mechanical stress achieved via surgical ventricular reconstruction. We de-
veloped a murine model of surgical ventricular reconstruction that would facilitate molecular analysis of the post-
reconstruction myocardium and allow future exploitation of genetic models.
Methods: C57/B6 mice underwent coronary artery ligation. For surgical ventricular reconstruction at 4 weeks
after myocardial infarction, a purse-string suture (7–0 polypropylene) achieved at least partial exclusion of the
apical aneurysm. Serial echocardiography was correlated to measurements of apoptosis and to Western blot anal-
ysis of key signaling cascades.
Results: An immediate 21.7% 2.6% improvement in fractional shortening was seen in the remaining myocar-
dium after surgical ventricular reconstruction. Reduction in left ventricular volume and improved function per-
sisted at 1 week, but recurrent dilatation at 4 weeks (left ventricular end-diastolic volume of 63.5  2.5 vs
42.1  5.4 mL immediately after reconstruction; P< .05) was associated with a loss of functional improvement
(fractional shortening 41.2%  2% vs 46%  0.9%; P< .01). At 1 week after surgical ventricular reconstruc-
tion, there was a transient reduction in myocardial apoptosis. A steady reduction in cardioprotective myocardial
Akt activation, however, was not affected by ventricular reconstruction.
Conclusion: This murine model recapitulates both the immediate benefits of surgical ventricular reconstruction
and the longer-term recurrence of dilated cardiomyopathy seen previously in some animal models and human
studies. Early analysis has begun to implicate persistent signaling changes in the postinfarction myocardium
that may be responsible for recurrent dilatation after surgical ventricular reconstruction and that may become tar-
gets for combined surgical and molecular interventions.
EVOLVING TECHNOLOGYCurrent management of congestive heart failure primarily
slows progression of disease. Surgical treatments have
been proposed to improve the biophysics of the dilated left
ventricle (LV) and to reduce the stimulus for ongoing path-
ologic remodeling.1 Early studies of surgical ventricular
reconstruction (SVR), and particularly of aneurysm resec-
tion, have demonstrated an improvement in both ventricular
function and congestive heart failure symptoms.2-8 These
studies, however, have also demonstrated recurrent LV dila-
tation, suggesting that a reduction in mechanical stress alone
does not address all of the changes in myocardial biology
that drive the remodeling process.4,8,9
Much has been learned regarding molecular signaling in
the myocardium. A number of pathways have been identi-
fied that drive both ventricular hypertrophy and a transition
to dilated cardiomyopthay.10 Genetic mouse models have re-
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doi:10.1016/j.jtcvs.2008.09.038942 The Journal of Thoracic and Cardiovascular Suvealed changes in even a single enzyme that can influence
macroscopic ventricular structure and function.11-15 In par-
ticular, phosphotidyl inositol-3 kinase (PI3K)/Akt signaling
can protect cardiac myocytes from apoptosis,11,16 although
the pathway has been associated with both pathologic hyper-
trophy12 and adaptive, physiologic hypertrophy.11 Mitogen-
activated protein (MAP) kinases also help determine cardiac
myocyte and ventricular fate; p38 MAP kinase and Jun N-
terminal kinase (JNK) have, in some studies, been associated
with cardiac cell apoptosis and ventricular dilatation,13,14
whereas the MAP kinase ERK (extracellular signal-related
kinase) may protect these cells.15
We describe a murine model of post–myocardial infarction
(MI) heart failure and SVR that may help elucidate the
molecular mechanisms of recurrent ventricular dilatation.
We hypothesize that critical changes in myocardial signaling
persist despite ventricular reconstruction (Figure 1) and that
hybrid molecular and surgical interventions may sustain
and even enhance benefit. We measured the activation of
key elements of the PI3K/Akt and MAP kinase cascades in
post-MI hearts subjected to either SVR or sham reoperation.
MATERIALS AND METHODS
Mouse Coronary Ligation and SVR
Male C57/B6 mice (25 g) were anesthetized with 1.5% inhaled isoflur-
ane at 115 breaths/min. A left lateral thoracotomy incision at the fourth in-
tercostal space exposed the LV and atrial appendage. Although mousergery c April 2009
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TAbbreviations and Acronyms
EF ¼ ejection fraction
ERK ¼ extracellular signal-related kinase
FS ¼ fractional shortening
JNK ¼ Jun N-terminal kinase
LAD ¼ left anterior descending coronary artery
LV ¼ left ventricle
LVEDV ¼ left ventricular end-diastolic volume
LVESV ¼ left ventricular end-systolic volume
MAP ¼ mitogen-activated protein
MI ¼ myocardial infarction
PI3K ¼ phosphotidyl inositol-3 kinase
SVR ¼ surgical ventricular reconstruction
TUNEL ¼ terminal deoxynucleotidyl transferase–
mediated dUTP nick end labeling
coronary anatomy differs from that of the typical human heart, there is gen-
erally at least one large branch of the left main coronary artery on the ante-
rior wall of the LV. A 7–0 polypropylene suture was used to ligate this
vessel, which, for convenience, we refer to as the left anterior descending
artery, approximately one third the distance from the base to the apex. Pre-
liminary studies documented a reproducible MI of 30% to 40% of the LV
as assessed by computerized image analysis (Scion Corp, Frederick, Md). A
sodium hyaluronate–carboxymethyl cellulose membrane patch (Seprafilm;
Genzyme Corporation, Cambridge, Mass) was placed between the LV and
chest wall to facilitate reoperation. SVR 4 weeks after MI involved place-
ment of a purse-string suture (7–0 polypropylene) around the infarcted/
aneurysmal region. Sham operation consisted simply of redo thoracotomy.
A total of 56 mice with left anterior descending artery ligation were ran-
domly divided into (1) sham control (20 mice) and (2) SVR (36 mice). Mor-
tality from thoracotomy was less than 10% and approximately 20% with
SVR. Significant morbidity was limited primarily to failure to thrive after
MI. Diastolic arrest was induced by high potassium injection at the time
the animals were humanely killed. All procedures conformed with the
‘‘Guide for the Care and Use of Laboratory Animals’’ published by the Na-
tional Institutes of Health (NIH Publication No. 85-23, revised 1996) and
were approved by the Institutional Animal Care and Use Committee of
the San Francisco Veterans Affairs Medical Center.
Echocardiography
Transthoracic echocardiography was performed on awake, minimally re-
strained mice with an Acuson Sequoia 512 machine (Siemens AG, Berlin,
Germany) and a 13-MHz probe. A 2-dimensional short-axis view of the LV
was obtained at the level of the papillary muscles, and M-mode tracings
were recorded. LV fractional shortening (FS) was calculated as LV diastolic
dimensionLV systolic dimension.17,18 Measurements were made before
and immediately after SVR and at 1, 2, and 4 weeks.
Histology and Apoptosis
Mouse hearts arrested in diastole were pressure-fixed in formalin and
paraffin-embedded. Serial sections (5 mm) were stained with Gomori tri-
chrome to identify fibrillar, collagen-rich scar. For apoptosis, thin sections
underwent TUNEL (terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling) staining (Chemicon, Temecula, Calif) and apopto-
tic indices were calculated in 3 sections per heart. Ligase staining (Apop-
Tag. Peroxidase ISOL Kit, Chemicon) of selected adjacent sections was
used to confirm the specificity of TUNEL.The Journal of Thoracic and CProtein Expression Analysis
Hearts were divided into infarct/border zone (defined as the translucent
infarct tissue plus the immediate 1 mm of surrounding myocardium) and
remote, uninfarcted myocardium and were homogenized in a lysis buffer
(0.13 mol/L KCl, 1 mmol/L ethylenediaminetraacetic acid, 1 mmol/L
ethyleneglycol tetraacetic acid, 1 mmol/L Na3 (vanadate ion), 5 mmol/L
sodium fluoride, 20 mmol/L N-2-hydroxyethyl-1-piperazine-N-2-ethane-
sulfonic acid (HEPES), and protease inhibitor cocktail tablet (Roche
Diagnostics, Mannheim, Germany). BCA Protein Assay Reagent Kit
(Pierce, Rockford, Ill) was used to measure protein concentration. Equal
amounts of protein were separated by NuPAGE Novex Bis-Tris Gels
(Invitrogen Corporation, Carlsbad, Calif) and transferred to polyvinylidene
fluoride membranes (Invitrogen Corporation). Blots were probed with an-
tibodies specific for phosphorylated Akt and total Akt, phosphorylated
ERK and total ERK, phosphorylated p38 and total p38, phosphorylated
p70S6 kinase and total p70S6 kinase, Bcl-2, Bax, or BAD (Cell Signaling,
Beverly, Mass) with appropriate horseradish peroxidase–conjugated
antibodies as secondary antibodies (Cell Signaling). SuperSignal West
Femto Maximum Sensitivity substrate (Pierce Biotechnology, Rockford,
Ill) was used for visualization. Density analysis by Scion Image (Scion
Corporation, Frederick, Md) was used to determine relative protein quan-
titification.
Statistics
Data are reported as mean  SEM. Comparisons between groups were
made with the t test and analysis of variance.
RESULTS
SVR With Partial Aneurysm Exclusion
Trichrome staining of a representative mouse heart imme-
diately after SVR demonstrated the exclusion of the majority
of postinfarct LV aneurysms, with subsequent alteration of
LV chanber size and geometry (Figure 2). The inability to
access the septal component of an infarct and excessive mor-
tality with overly aggressive purse-string reductions in LV
size resulted in only partial aneurysm exclusion in many an-
imals (Figure 2).
Immediate Effect of SVR on LV End-Diastolic
Volume and Redilation
Echocardiography confirmed similar LV end-diastolic
volume (LVEDV), end-systolic volume (LVESV), and FS
between the groups that were subsequently randomized to
either SVR or sham control at 4 weeks after left anterior
descending artery ligation. Immediately after SVR, we ob-
served an anticipated reduction in LV dimensions (Figure 3,
A) and LVEDV (42.1  5.4 vs 69.0  5.8 mL; P<.01; Fig-
ure 3, B). No differences were observed in LV volumes after
sham operation. Serial echocardiography demonstrated that
the LVEDV gradually increased after SVR (Figure 3, B) and
that LVEDV in the post-SVR animals was no longer statis-
tically different from that in the sham group, or pre-SVR
levels, by 4 weeks after reoperation.
Ejection Fraction (EF) and FS Status-Post SVR
Echocardiography was chosen as a primary functional
analysis because it may be the only modality capable ofardiovascular Surgery c Volume 137, Number 4 943
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TFIGURE 1. Hypothesized role of persistent pathologic signaling motif in the recurrence of ventricular dilatation after SVR. Immediate reduction in LV wall
stress leads to a reduction in apoptotic stimuli, whereas persistent alterations in fundamental myocardial signaling pathways, such as PI3K/Akt and MAP
kinase cascades, drive ongoing SVR. A return of ventricular dilatation and resultant wall stress leads to a return of apoptotic myocyte loss. SVR, Surgical
ventricular remodeling; LV, left ventricular; MAP, mitogen-activated protein.measuring cardiac function in awake, minimally restrained
mice, thereby eliminating the profound impact of general an-
esthesia on cardiac function in rodents. Furthermore, it al-
lowed serial measurements in the same animals, believed
to be critical for this study of SVR. Focusing the analysis
of FS at the level of the more easily identifiable mitral appa-
ratus helped standardize the echocardiographic imaging,
which was carried out in a blinded fashion. Echocardio-
graphic evidence of improved hemodynamic function imme-
diately after SVR was corroborated in a small number of
hearts via ex vivo Langendorff preparation (data not shown).
Echocardiography revealed an improvement in ejection
fraction (EF) after SVR that corresponded to the reduction
in LV chamber size (74.5%  0.6% vs 66.9%  1.4% be-
fore SVR; P<.01). While a reduction in volume can directly
lead to an improvement in EF, even more striking was an im-944 The Journal of Thoracic and Cardiovascular Suprovement in FS (21.7%  2.6% improvement over pre-
SVR) measured in the myocardial wall at the level of the
proximal mitral apparatus, distant from the region of the in-
farct (Figure 4). These data suggest that an immediate reduc-
tion in LV wall stress allowed a functional improvement in
more global myocyte contractility. By 4 weeks after SVR,
however, serial echocardiography indicated a significant de-
cline in both EF and FS (Figures 3, B, 4). Parameters of LV
function in the sham controls remained relatively stable dur-
ing this time period.
Apoptosis and Expression of Apoptotic Regulators in
the Post-SVR Ventricle
Previous studies have suggested that LV dilatation is me-
diated at least in part through the loss of cardiac myocytes
to programmed cell death, or apoptosis. We thereforeFIGURE 2. Gamori trichrome stain of mouse heart 4 weeks after myocardial infarction with (B) or without (A) surgical ventricular remodeling (SVR).rgery c April 2009
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TFIGURE 3. A, Echocardiograms of infarcted hearts before and immediately after SVR. SVR decreased both the long axial length and cross-sectional area of
the LV chamber, as indicated by dashed lines. B, Time course of LVEDV, LVESV, and EF status-post SVR. The LVEDV, LVESV, and EF all improved
immediately after SVR (yP< .01) but gradually returned to approximate pre-SVR levels (*P< .05 vs levels immediately after SVR) (n ¼ 8). EF, Ejection
fraction; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; SVR, surgical ventricular reconstruction.measured both rates of myocardial apoptosis and the protein
expression levels of several key mediators of apoptosis in
the post-SVR ventricle and compared them with those in
sham controls (Figure 5, A and B). The regulation of apopto-
sis is characterized by an intricate balance between proteins
that play antiapoptotic and proapoptotic roles. Although
levels of the antiapoptotic protein Bcl-2 did not change sig-
nificantly between weeks 1 and 4 after reoperation, either in
SVR or sham control animals, a decrease in expression of
proapoptotic Bax resulted in an increase in the Bcl-2/Bax ra-The Journal of Thoracic andtio at week 1 after reoperation compared with normal hearts
(Figure 5, C). This increase was more pronounced in SVR
versus sham controls (P< .05). By week 4, this ratio in
both groups returned to levels seen in normal hearts. This
early antiapoptotic signal was counterbalanced in sham
controls by a drop in proapoptotic BAD phosphorylation
(inactivation) at week 1 (Figure 5, D). Interestingly, BAD
phosphorylation remained at normal levels in SVR hearts
at 1 week, at which time apoptotic indices were down. Early
after reoperation, levels of antiapoptotic Bcl-XL expressionCardiovascular Surgery c Volume 137, Number 4 945
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Twere decreased but then increased very significantly in both
treatment groups at week 4 (Figure 5, E).
Changes in Myocardial Signaling
Compared with normal myocardium, post-MI sham con-
trol hearts displayed a progressive decrease in Akt activation
(as reflected in the relative phosphorylation of Akt on West-
ern blot, Figure 6, A), and this drop in cardioprotective sig-
naling was not affected by SVR. A small increase was
observed at week 1 after reoperation in phosphorylation
(ie, activation) of MAP kinase p38 in sham controls,
although, in general, levels of p38 phosphorylation did not
vary substantially between SVR and sham controls (Figure 6,
B). Similarly, increases in ERK phosphorylation (ie, activa-
tion) were seen in both sham controls and SVR hearts at
week 1 after reoperation, although there was a return to base-
line ERK phosphorylation in SVR, but not sham, hearts at
week 4 (Figure 6, C). Interestingly, a drop in phosphorylation
(ie, activation) of JNK was observed only in sham control
hearts at week 1, although phosphorylation of this so-called
stress-activated kinase, associated in some studies with myo-
cardial apoptotsis, was increased above baseline in normal
hearts in both treatment groups at week 4 (Figure 6, D).
DISCUSSION
In our murine model, SVR improved cardiac function.
These reconstructed ventricles, however, were susceptible
to recurrent dilatation, and a reduction in function was ob-
served as early as 4 weeks after reconstruction. These results
are similar to the findings of Nishina and associates3,19 in
a rat model of aneurysm exclusion and are reminiscent of
longer-term changes documented in clinical studies of linear
or patch ventricular repair.20-22
The complex integration of multiple signaling pathways is
not yet well understood in the evolution of post-MI cardio-
myopathy. However, studies have suggested a cardioprotec-
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FIGURE 4. Changes in FS status-post SVR. An immediate improvement
in FS in the SVR group persisted at week 1 (*P< .05, n ¼ 24–26) but not
week 4 after SVR, whereas no significant change in FS was seen in the
sham group (n ¼ 9). FS, Fractional shortening; SVR, surgical ventricular
remodeling.946 The Journal of Thoracic and Cardiovascular Sutive role for the PI3K/Akt pathway.23,24 The drop we
observed in Akt phosphorylation in the post-MI myocar-
dium may therefore play an important role in the loss and
dysfunction of myocardial tissue; this drop persisted even
after an improvement in ventricular geometry achieved via
SVR.
Only minor differences were observed between sham con-
trol and SVR hearts in terms of the phosphorylation of MAP
kinases p38 and ERK early after reoperation. MAP kinase
activation is generally upregulated after ischemic insults, al-
though the role of this activation has been studied more ex-
tensively in the progression from pressure overload–induced
hypertrophy to dilated cardiomyopathy. It is not clear what
role, if any, the observed reduction in phosphorylation of
JNK, generally considered, like p38, a ‘‘stress-induced’’ ki-
nase, might have played in sham control hearts 1 week after
reoperation, although this change was not observed in SVR
hearts. JNK phosphorylation was then increased in both
groups by week 4.
SVR results in a reduction in ventricular volume and a de-
crease in chamber radius. According to LaPlace’s law, these
changes decrease wall stress. A reduction in wall stress re-
duces myocardial oxygen demand and enhances ventricular
contraction,9 and there is an increase in the extent and veloc-
ity of systolic fiber shortening. This phenomenon was re-
flected in the increases in FS and EF observed in our
murine model. In addition, SVR is likely associated with
acute and subacute changes in hemodynamic parameters,
which, in turn, are likely to affect both ventricular remodel-
ing and associated changes in myocyte signaling. Future
studies may be necessary to sort out the various stimuli for
changes in cardiac myocyte gene expression and kinase ac-
tivation to optimize human translation of these interventions.
Furthermore, a reduction in mechanical stress may have
also contributed to the reduced level of myocardial apoptosis
seen early after SVR, and that may have been mediated by an
increase in the Bcl-2/ Bax ratio and a preservation of BAD
phosphorylation. As suggested by the schema in Figure 1,
persistent changes in molecular signaling, however, such
as the reduction of Akt phosphorylation, may drive cardiac
remodeling at the cellular level, even after SVR. Subsequent
recurrence of LV dilatation could, in turn, instigate a return
to pathologic levels of wall stress and to the vicious cycle of
apoptotic cell loss and further progressive LV enlargement.
Current surgical treatments for ischemic cardiomyopathy
may not yield optimal long-term outcomes.2,7 This study
explored changes in myocardial signaling that might induce
reverse remodeling or ‘‘physiologic hypertrophy’’ to comple-
ment the immediate improvement in ventricular geometry
achieved by SVR. In addition, cell-based and tissue-engineer-
ing approaches may be combined with reconstruction. Nu-
merous studies have demonstrated benefit from stem cell
delivery to injured myocardium,25-27 and more recent reports
have also described bio-artificial matrices that may providergery c April 2009
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Techanical support to the injured myocardium and enhance
yocardial regeneration.28,29 The direct access of the surgeon
t the time of SVR may facilitate otherwise challenging, early
pplications of these approaches.
Like any small animal model, ours must be understood in
light of its numerous limitations. We induced acute MI in the
setting of otherwise normal coronary anatomy and function;
more complex human disease may be better mimicked
IGURE 5. SVR effect on the survival of cardiomyocytes in the remote myocardium. Apoptotic indices derived from TUNEL staining (A) were lower at 1
eek (yP<.01) but not at 4 weeks (P¼ not significant) in SVR hearts compared with sham controls (B). The ratio of expressions of Bcl-2/Bax (C), expression
f Bcl-XL (D), and phosphorylation (inactivation) of proapoptotic BAD (E) in sham control and SVR hearts at 1 and 4 weeks after reoperation. (yP<.01,*P<
05, n ¼ 3). SVR, Surgical ventricular reconstruction.The Journal of Thoracic and Cardiovascular Surgery c Volume 137, Number 4 947
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TFIGURE 6. Myocardial signaling after SVR. Patterns of phosphorylation (activation) of Akt (A) and of MAP kinases p38 (B), ERK 1/2 (C), and JNK (D) at 1 and
4 weeks after reoperation in SVR and sham control hearts (yP<.01, *P<.05, n¼ 3–4). SVR, Surgical ventricular reconstruction.MAP,mitogen-activated protein.through application of this model in genetic mouse models
of diffuse coronary atherosclerosis. In addition, permanent
coronary occlusion resulted in a large transmural infarc-
tion/aneurysm that exaggerates the typical infarctions of
modern candidates for aneurysm resection. Future variations
of this model, such as temporary ligation, may extend these
observations toward a broader range of human clinical sce-
narios. The rapid progression of LV remodeling after MI in
mice, and of recurrent dilatation after SVR, may require
transition through larger animal models for accurate extrap-
olation to human translation.
If one key to recurrent LV dilatation, however, lies in the
molecular biology of the cardiac myocyte,30 then the murine948 The Journal of Thoracic and Cardiovascular Sumodel described here may be well suited to identify critical
molecular pathways in the response of the ventricle to SVR.
The relative ease with which transgenic strains can be devel-
oped in mice has already yielded a wide array of available
genetic models. Interestingly, the rapid progression of recur-
rent dilatation in mice may provide an advantage in the early
discovery process. Ongoing studies have begun to examine
SVR in the context of myocardial overexpression of acti-
vated Akt in transgenic mice. Data from these and other
studies may, in turn, provide a foundation for the develop-
ment of novel, hybrid surgical interventions for failing
hearts, in which genetic, molecular, or cell-based therapies
may be applied intraoperatively on the basis of a morergery c April 2009
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Tdetailed appreciation of the molecular and cellular parame-
ters of ventricular recovery after reconstruction.
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